Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
Kamata
Y
Y
Kamimura
T
T
Iwamoto
M
M
Minota
S
S
D000368:Aged; D000527:Alprostadil / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D011928:Raynaud Disease / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D000527:Alprostadil